Bestill og last ned pasient- og informasjonsmateriell innenfor ditt terapiområde
Velg materiell her:
REPRINT; Sharman, Elevate TN, Title: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Reprint; Elevate-TN Author: Sharman, Paper: Leukemia
ELEVATE RR Study
Behandlingsveiledning for leger og sykepleiere - Calquence.
NO HCP Brochure for Lynparza in Prostate Cancer, including both PROpel and PROfound results .
Pivotal HIMALAYA Study Publication. Published June 6, 2022 NEJM Evid 2022; 1 (8) DOI:https://doi.org/10.1056/EVIDoa2100070
TOPAZ-1 phase 3 trial published in the New England Journal of Medicine. Published June 1, 2022 NEJM Evid 2022; 1 (8) DOI:https://doi.org/10.1056/EVIDoa2200015. The basis of the TOPAZ-1 EMA approval (19/12-2022)
Nordic Reprint: HIMALAYA 4Y. Sangro, B.Azevedo, Sergio et al. Annals of Oncology 2024
Peer-reviewed study aiming to investigate TOPAZ-1 in a real-world setting. The results reported in this first real-world analysis mostly confirmed the results achieved in the TOPAZ-1 trial in terms of PFS, ORR and safety in a Western Population. Annals of Oncology 2024
This first global real-world analysis largely confirmed the TOPAZ-1 findings, supporting gemcitabine, cisplatin, and durvalumab as a first-line standard of care for patients with advanced BTC. Published in September 2024.
TOPAZ-1 phase 3 trial published in the New England Journal of Medicine. Published June 1, 2022 NEJM Evid 2022; 1 (8) DOI:https://doi.org/10.1056/EVIDoa2200015. The basis of the TOPAZ-1 EMA approval (19/12-2022).
Pivotal HIMALAYA Study Publication. Published June 6, 2022 NEJM Evid 2022; 1 (8) DOI:https://doi.org/10.1056/EVIDoa2100070.
Peer-reviewed study aiming to investigate TOPAZ-1 in a real-world setting. The results reported in this first real-world analysis mostly confirmed the results achieved in the TOPAZ-1 trial in terms of PFS, ORR and safety in a Western Population.
Peer-reviewed updated analysis of the phase III HIMALAYA study in uHCC. First IO HCC study to publish survival data at 4Y. Original article Volume 35, Issue 5 p448-457May 2024.
Brochure for oncologists about HER2-low testing.
Brochure for pathologists about HER2-low patient identification.
Reporting guide for pathologists about HER2 in mBC.
HER2 IHC scoring guide: Interpretation of staining in breast carcinomas.
Fyll ut detaljene nedenfor for å bekrefte og fortsette med bestillingen din.
Har du allerede registrert deg som bruker, LOGG INN, og så fylles dine opplysninger automatisk ut og du kan bruke dine tidligere bestillinger på nytt.
Vær oppmerksom på at vi ikke kan levere bestillinger til postbokser
Registrer deg på AstraZeneca Connect (frivillig)
Ja, jeg vil opprette en konto på AstraZeneca Connect og få de fordelene som registreringen medfører.
Jeg har lest og godtar brukervilkårene som finnes i AstraZenecas personvernerklæring.
